https://www.selleckchem.com/pr....oducts/pexidartinib-
The SUD treatment providers were almost twice as likely as the public sample (OR = 1.81, 95% CI = 1.27-2.59) and the public sample almost twice as likely as the medical treatment providers (OR = 1.74, 95% CI = 1.24-2.47) to endorse the use of incentives to treat more SUDs. Medical treatment providers were also the least likely to endorse incentives to treat both legal and illicit substance use. These findings suggest that incentive programs have good acceptability among SUD treatment providers and the public, but medical tr
Curtir
Comentario
Compartilhar
